Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Prolifer...
Name
Merck and Company
Anticipated Amount
408 663.00
Activity Type
Clinical Trial
Award Type
Contract
Date
July 8, 2012 to August 29, 2014
Award Number
005649-00001
Sponsor Award Number
MK-8669-064-13
Award Contacts
Name
Stopeck,Alison T
Title
Principal Investigator
Unit
Medicine